Omega‐3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial

Abstract

Background

Supplementation with omega‐3 polyunsaturated fatty acids (ω‐3 PUFA) and low‐dose aspirin (ASA) have been proposed as a host modulation regimen to control chronic inflammatory diseases. The aim of this study was to investigate the clinical and immunological impact of orally administered ω‐3 PUFA and ASA as adjuncts to periodontal debridement for the treatment of periodontitis in patients type 2 diabetes.

Methods

Seventy‐five patients (n = 25/group) were randomly assigned to receive placebo and periodontal debridement (CG), ω‐3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) after periodontal debridement (test group [TG]1), or ω‐3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) before periodontal debridement (TG2). Periodontal parameters and GCF were collected at baseline (t0), 3 months after periodontal debridement and ω‐3 PUFA + ASA or placebo for TG1 and CG (t1), after ω‐3 PUFA + ASA (before periodontal debridement) for TG2 (t1), and 6 months after periodontal debridement (all groups) (t2). GCF was analyzed for cytokine levels by multiplex ELISA.

Results

Ten patients (40%) in TG1 and nine patients (36%) in TG2 achieved the clinical endpoint for treatment (less than or equal to four sites with probing depth ≥ 5 mm), as opposed to four (16%) in CG. There was clinical attachment gain in moderate and deep pockets for TG1. IFN‐γ and interleukin (IL)‐8 levels decreased over time for both test groups. IL‐6 levels were lower for TG1. HbA1c levels reduced for TG1.

Conclusion

Adjunctive ω‐3 and ASA after periodontal debridement provides clinical and immunological benefits to the treatment of periodontitis in patients with type 2 diabetes.

from
https://aap.onlinelibrary.wiley.com/doi/abs/10.1002/JPER.19-0613?af=R